Show simple item record

dc.contributor.authorKhan, Nazish
dc.contributor.authorMamas, Mamas A.
dc.contributor.authorMoss, Alexandra
dc.contributor.authorGorog, Diana A.
dc.contributor.authorNightingale, Peter
dc.contributor.authorArmesilla, Angel
dc.contributor.authorSmallwood, Andrew
dc.contributor.authorMunir, Shahzad
dc.contributor.authorKhogali, Saib
dc.contributor.authorWrigley, Ben
dc.contributor.authorCotton, James M.
dc.date.accessioned2020-11-11T00:15:12Z
dc.date.available2020-11-11T00:15:12Z
dc.date.issued2020-09-10
dc.identifier.citationKhan , N , Mamas , M A , Moss , A , Gorog , D A , Nightingale , P , Armesilla , A , Smallwood , A , Munir , S , Khogali , S , Wrigley , B & Cotton , J M 2020 , ' Aspirin related platelet reactivity as a determinant of ten year survival in high risk non-ST segment elevation myocardial infarction (NSTEMI) patients ' , Thrombosis Research , vol. 196 , pp. 523-525 . https://doi.org/10.1016/j.thromres.2020.09.011
dc.identifier.issn0049-3848
dc.identifier.otherPURE: 22962995
dc.identifier.otherPURE UUID: 7036687d-699a-4b67-8fb1-2ab3caa18892
dc.identifier.otherScopus: 85093663764
dc.identifier.urihttp://hdl.handle.net/2299/23433
dc.description.abstractAspirin, the most commonly prescribed antiplatelet agent in clinical practice, forms a cornerstone of management in patients with established cardiovascular disease (CVD). The clinical efficacy and safety of aspirin when prescribed for secondary prevention is supported by a robust evidence base demonstrating a 24% reduction in mortality and a 25% reduction in serious adverse events without any increase in bleeding complications in the context of an acute myocardial infarction [ 1 ]. Nevertheless, numerous studies have shown that the antiplatelet effect of aspirin is not uniform and is often sub-optimal in a sizable proportion of patients [ 2 , 3 ]. Inadequate platelet inhibition following the administration of aspirin is associated with recurrent cardiovascular events and adverse outcomes in patients with coronary artery disease [ 2 ].en
dc.format.extent3
dc.language.isoeng
dc.relation.ispartofThrombosis Research
dc.subjectAspirin resistance
dc.subjectMortality
dc.subjectNSTEMI
dc.subjectHematology
dc.titleAspirin related platelet reactivity as a determinant of ten year survival in high risk non-ST segment elevation myocardial infarction (NSTEMI) patientsen
dc.contributor.institutionDepartment of Pharmacy, Pharmacology and Postgraduate Medicine
dc.contributor.institutionDepartment of Clinical, Pharmaceutical and Biological Science
dc.description.statusPeer reviewed
dc.date.embargoedUntil2021-09-10
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85093663764&partnerID=8YFLogxK
rioxxterms.versionAM
rioxxterms.versionofrecordhttps://doi.org/10.1016/j.thromres.2020.09.011
rioxxterms.typeOther
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record